Synthesis,
Structure–Activity Relationships, and in Vivo Efficacy of the
Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor
5‑Chloro‑N2‑(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)‑N4‑(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine
(LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, AnneMarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves

doi:10.1021/jm400402q.s001

jm400402q_si_001.pdf (913.86 kB)

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5‑Chloro‑N2‑(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)‑N4‑(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

journal contribution

posted on 2013-07-25, 00:00 authored by Thomas H. Marsilje, Wei Pei, Bei Chen, Wenshuo Lu, Tetsuo Uno, Yunho Jin, Tao Jiang, Sungjoon Kim, Nanxin Li, Markus Warmuth, Yelena Sarkisova, Frank Sun, Auzon Steffy, AnneMarie C. Pferdekamper, Allen G. Li, Sean B. Joseph, Young Kim, Bo Liu, Tove Tuntland, Xiaoming Cui, Nathanael S. Gray, Ruo Steensma, Yongqin Wan, Jiqing Jiang, Greg Chopiuk, Jie Li, W. Perry Gordon, Wendy Richmond, Kevin Johnson, Jonathan Chang, Todd Groessl, You-Qun He, Andrew Phimister, Alex Aycinena, Christian C. Lee, Badry Bursulaya, Donald S. Karanewsky, H. Martin Seidel, Jennifer L. Harris, Pierre-Yves Michellys

The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure–activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients.

History

Usage metrics

Categories

Keywords

Licence

Exports